Search

A recent study conducted at Nanjing University in China has developed a new type of boron delivery agent for boron neutron capture therapy (BNCT) in cancer treatment. The agent combines aggregation-induced emission (AIE)-active imaging, a carborane cluster, and an erlotinib targeting unit for lung cancer cells. The boron delivery agents demonstrated excellent imaging properties and selective accumulation in tumors, resulting in highly efficient tumor growth suppression without observable tissue damage. This study expands the application of AIE-active molecules and boron clusters and provides a new molecular engineering strategy for cancer therapy based on BNCT. [Extracted from the article]